IceCure Medical Ltd Q2 2025 Earnings Recap

ICCM Q2 2025 August 13, 2025

Get alerts when ICCM reports next quarter

IceCure Medical's first half of 2025 demonstrated strategic regulatory progress for its ProSense device despite a revenue decline attributed to external shipment delays, while strengthening its financial position through a successful rights offering.

Earnings Per Share Beat

$-0.06 vs $-0.06 est.

+0.0% surprise

Revenue Miss

525000 vs 639000 est.

-17.8% surprise

Market Reaction

1-Day +0.19%

5-Day +2.38%

30-Day +25.0%

See ICCM alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue fell to $1.25 million, down from $1.75 million due to shipment delays linked to the Israel-Iran conflict.
Gross profit decreased to $349,000, resulting in a gross margin contraction to 28% from 46% year-over-year.
The company closed a $10 million rights offering, significantly oversubscribed, providing a robust cash runway for anticipated FDA marketing authorization.
Positive adoption trends in Europe were noted, driven by clinical evidence and a string of high-impact presentations at medical conferences.
Anticipation of FDA approval for ProSense remains optimistic, with plans for a post-market study already submitted.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ICCM on AllInvestView.

Next Q3 2025